http://www.pharmainfocus.com.au/opinion.asp?opinionid=278

Last week was an important one for watchers of the continuing debate
over pharmaceutical industry influence on medical and healthcare
professionals. Developments overseas and in Australia showed that the
march towards greater transparency is gaining pace.

In the US, Merck has added its name to the list of major pharma
companies that have voluntarily decided to publish payments made to
doctors on their corporate websites.

It joins Pfizer, Eli Lilly and GlaxoSmithKline in either disclosing or
pledging to disclose payments for such activities as consulting,
speaking and writing. GSK has also said it will cap payments at US
$150,000 to any one doctor.